Last reviewed · How we verify
NCT04739098
Initial Manifestations of Congestive Heart Failure in Patients With NSTEACS
trial in Acute Heart Failure, Non-ST-segment Elevation Acute Coronary Syndrome in 200 participants. Status unknown.
2 May 2023
Quick facts
| Lead sponsor | National Medical Research Center for Therapy and Preventive Medicine |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 30 January 2020 |
| Primary completion | 2 May 2023 |
| Estimated completion | 28 August 2024 |
| Sites | 1 location across Russia |
Conditions studied
- Acute Heart Failure, Non-ST-segment Elevation Acute Coronary Syndrome — all drugs for Acute Heart Failure, Non-ST-segment Elevation Acute Coronary Syndrome →
Sponsor
National Medical Research Center for Therapy and Preventive Medicine
Who can join
18 and older, any sex, with Acute Heart Failure, Non-ST-segment Elevation Acute Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Acute heart failure (HF) is a common complication of acute coronary syndrome (ACS) associated with poor prognosis. Diagnosis of congestive HF in patients with initial, non-severe symptoms and signs may be challenging and early stages of this complication may be missed. To assess severity of HF in patients with ACS Killip classification is widely used but it does not take into account mild manifestations of HF. Thus, patients without rales in the lungs and/or S3 will be labelled as Killip class 1. The aim of this study is to determine the frequency, risk factors, abilities for early diagnosis using routine medical evaluation and clinical significance of subclinical and mildly symptomatic congestive HF in patients with ACS without persistent ST-segment elevation (NSTEACS). The study will include 200 patients with NSTEACS without history of severe HF and overt signs of congestion at presentation. Presence and severity of dyspnea (according to Likert ans Visual analog scales), physical signs of heart failure (respiratory rate, distention of jugular veins, S3), peripheral oxygen saturation by pulse oximetry, heart rate and signs of ischemia on ECG, signs of congestion according to lung and vena cava inferior ultrasound and chest X-Ray/CT as well as levels of NT-proBNP, hsTn, CRP and FABP at presentation will be evaluated. Presence and severity of dyspnea, physical signs of heart failure, oxygen saturation, heart rate and signs of ischemia on ECG, lung and vena cava inferior ultrasound will be re-assessed after 6, 12 and 24 hours. During hospitalization occurrence or worsening of clinical HF. Clinical events will be followed up to 12 months after hospitalization.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04739098
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other National Medical Research Center for Therapy and Preventive Medicine trials
Trials by the same sponsor.
- NCT07375433 — Heart Failure With Preserved Ejection Fraction in Patients With Сhronic Obstructive Pulmonary Disease: Clinical Course a · recruiting
- NCT07040800 — Adherence to Pharmacotherapy in Patients Admitted for Inpatient Treatment at the Scientific Medical Center (PRIMULA) · active not recruiting
- NCT06845384 — Registry of Acute Coronary Syndrome in the Regional Cardiovascular Center · active not recruiting
- NCT06803849 — Association of Heterogeneous Circulating Biomarkers and Anamnestic Factors of Pregnancy Adverse Course and Outcomes With · recruiting
- NCT06845397 — Chuvashia Inappropriate Prescribing Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04739098 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Medical Research Center for Therapy and Preventive Medicine
- Last refreshed: 1 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04739098.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing